Joint Programming in Neurodegenerative Disease Research (JPND)

Coordinating approaches to research across Europe

Adriana MaggiVice-Chair, JPND Executive Board

26/10/2013

A new Member States-led initiative in Europe which aims to address “grand challenges” to EU society by coordinating national research programmes within the EU to increase the impact and effectiveness of research efforts.

What is Joint Programming?

COST OF DISORDERS OF THE BRAIN IN EUROPE

Estimates in 2004

Estimates in 2010

(1) Referred to as “effective disorders” in 2005, (2) includes only incident cases in 2010, (3) weighted mean from all countries and diagnoses(5) including also persons with zero costs, (6) excluding indirect costs, (7) excluding PTSD (European Neuropsychopharmacology (2011) 21, 718-779)

A global health and economic emergency

• Between now and 2050, over 680 million new cases of dementia will be diagnosed worldwide 1

• That’s 680 million people living with dementia in the next 40 years! • more than the population of all of North America (542 million) and nearly as

much as all of Europe (738 million)

• ND are the most expensive of all known diseases• Global cost of dementia in 2010 is $604 billion - 1% of global GDP 2

• Current economic crisis is affecting research budgets

A global health and economic emergency

• Between now and 2050, over 680 million new cases of dementia will be diagnosed worldwide 1

• That’s 680 million people living with dementia in the next 40 years! • more than the population of all of North America (542 million) and nearly as

much as all of Europe (738 million)

• ND are the most expensive of all known diseases• Global cost of dementia in 2010 is $604 billion - 1% of global GDP 2

• Current economic crisis is affecting research budgets

1 – World Alzheimer Report 20122 – WHO Dementia Report 2012

AN EPIDEMICS FOR NEURODEGENERATION?

INCREASING AGE

LACK OF THERAPIES!

Impact of a 5-year delay on the onset by stage of

disease, Americans aged 65 and older with AD, 2050

Changing the trajectory

Proportion of American Age 65 and older with Azheimer Disease by Stage of Disease 2010-2050

What if we delay the onset and progression?

Cortesy M. Di Luca 2013

JPND - The Pilot Project in Joint Programming

We cannot tackle neurodegenerative diseases by acting as single countries

AlbaniaAustria

BelgiumCanadaCroatia

Czech RepublicDenmarkFinlandFrance

GermanyGreeceHungaryIrelandIsraelItaly

LuxembourgNetherlands

NorwayPoland

PortugalSlovakiaSlovenia

SpainSweden

SwitzerlandTurkey

United Kingdom

JPND is a global research initiative led by countries , with 27 member states, associated countries and third countries participating

JPND is currently supportedby FP7-JUMPAHEAD (GA. 260774)

Management Board27 countries representedChair Philippe Amouyel (France)

Executive BoardVice-Chair Adriana Maggi (Italy)Rob Buckle (UK)Marlies.Dorloechter) (Germany)Mogens Horder (Denmark)

Scientific Advisory Board18 Members Chosen for scientific excellence and competence

Organisation

Steering CommitteeExecutive Board+Edvard Beem (The Netherlands) Enda Connolly (Ireland)Rainer Girgenrath (Germany)Nihan Eryilmaz (Turkey)

DEFRAGMENTATION, THIS IS ALL WHAT JPND IS ABOUT

STRATEGIC RESEARCH AGENDA

ALIGNMENT OF EU COUNTRIESON COMMON RESEARCH GOALS

The SRA goals

To tackle the challenge of Alzheimer’s and other neurodegenerative diseases*, the goals of the JPND Research Strategy are:

* Alzheimer’s disease and other dementias (AD), Parkinson’s disease (PD) and PD-related disorders, Prion disease, motor neurone diseases (MND), Huntington’s disease (HD), Spinocerebellar ataxia (SCA), Spinal muscular atrophy (SMA)

• To develop new treatments and preventive strategies

• To improve health and social care approaches

• To raise awareness and de-stigmatise neurodegenerative disorders

• To alleviate the economic and social burden of these diseases

Implementation of the SRA

Launch calls aimed at harmonizing EU research in the field of Neurodegenerative Diseases

Organize working groups to create a list of opportunities suited for the SRA implementation

Stimulate the creation of national plans for dementia and aligne these programs

Identify strategies for the implementation of common infrastructures

What are the conditions that create a ripe environment for innovation?

Joint Transnational Calls

One in 2011 for €16 M

Two in 2012-2013 for €29 M

Two in 2013-2014 for about € 30 M

Centres of Excellence in

Neurodegeneration (CoEN) program

2011 for € 6M ; in 2012-13 for € 8M

night science wanders blind. It hesitates, stumbles, recoils, sweats, wakes with a start. […] There is no way to predict whether night science will ever become day science; whether the prisoner will emerge from the darkness

«Of flies, mice and man» Francois Jacob

Conscious of its progress, proud of its past, sure of its future, day science advances in light and glory

JPND Call for Proposals:

”European research projects for Cross-Disease Analysis of Pathways related to Neurodegenerative Diseases”

Submission deadline for proposals: 18th February 2014

•Canadian Institutes of Health Research•Finland, Academy of Finland •France, French National Research Agency•Germany, Federal Ministry of Education and Research •Italy

Ministry of Health Ministry of Education, Universities and Research

•Netherlands, The Netherlands Organisation for Health Research and Development •Norway, The Research Council of Norway •Poland, National Science Centre•Portugal, Foundation for Science and Technology•Slovakia, Ministry of Education, Science, Research and Sport of the Slovak Republic•Spain, National Institute of Health Carlos III•Sweden, Swedish Research Council •Turkey, Scientific and Technological Research Council of Turkey

VALI

DAT

ED M

OD

ELS

PATHWAYS

DIE

T

CH

OLE

STER

OL

DIS

EASE

DIA

GN

OSI

S

DIE

T

NEU

RO

NS

DEFRAGMENTATION, THE JPND APPROACH

Stimulate the creation of national plans for dementia and aligne these programs

NATIONAL DEMENTIA PLANS

“EC sees JPIs as Knowledge Hubs”

JPI e il programmaHorizon 2020

Robert Jan-Smith Direttore Generale DG Research and Innovationdell’European Commision

……e a livello Nazionale?

RAPPRESENTANTI ITALIANI NEL JPND

• Executive Board: Adriana Maggi, Unimi, Vice-chair

• Management Board: Maria Uccellatore, MIURFabrizio Tagliavini, IRCCS, Besta

• Comitato Scientifico: Stefano Cappa, IRCCS San Raffaele

• Action group: interazione con Industrie A.Maggi chair

• Action group: Experimental animals A.Maggi chair and F. Blandini, IRCCS Mondino

• Action group: Longitudinal cohorts S. Cappa

Carlo Caltagirone, Roma Stefano Cappa, MilanoGiovanni Frisoni, BresciaAdriana Maggi, MilanoAlessandro Padovani, BresciaPaolo Maria Rossini, RomaFabrizio Tagliavini, Milano

Gaetano Guglielmi, Min SalMaria Uccellatore, MIUR

Il gruppo di supporto alle attività JPND

Un piano nazionale per le demenze

Un piano nazionale per le demenze

……e a livello Nazionale?

le nostre preoccupazioni

Italian excellence in the field of neurodegeneration

3,1

4,3

3,33,7 3,9

2,7

0,0

1,0

2,0

3,0

4,0

5,0

neurodeg aging cancer

world

Italy

IF medio delle ultime 30 pubblicazioniapparse in Pub Med (16/6/2012)

EPOC-AD: EUROPEAN PLATFORM TO FACILITATE PROOF OF CONCEPT FOR PREVENTION IN

ALZHEIMER’S DISEASE

DRAFT PROPOSAL

Biomarkers and adaptive trial design in AD; a proposal

Stratification markers

Progression markers

High specificity, high intervention markerse.g. CSF or PET markers of pathology

Best combination of markerse.g. slope measurement in as short a time frame as possible

High sensitivity, low intervention markerse.g. blood based markers discovered by targeted endophenotype design

Unbiased, data-driven discoverye.g. wide range of assessments; short assessment period

Thanks to Simon Lovestone (King’s College, UK)

EPOC Proposal - DRAFT

• Let’s build a biomarker based GPS system to identify the position of subjects on their trajectory towards developing dementia

• To achieve this, let’s set up large scale longitudinal natural history study• Initially the study will learn about biomarker trajectories• Later the study may become a platform for

pharmacological intervention trials

Keep up to date

• Visit the JPND website:• http://www.neurodegenerationresearch.eu• http://www.jpnd.eu

• Search our Mapping Database

• Sign up to the JPND News Feeds

• E-mail us: secretariat@jpnd.eu

• Follow us on Twitter: @JPNDEurope

The next Challenges

• To continue implementation beyond phase I

• To partner with European Commission

• To partner with Industry

• To ensure JPND sustainability

Partnering with Industry

• Substantive participation in development of JPND Research Strategy

• Now Members of Scientific Advisory Board

• Ongoing discussions with EFPIA-IMI

• Enlarge the contacts (pharma, device, IT, diagnosis, imaging, welfare technologies, AAL, …)

• JPND Industry Action Group to develop new public-private-partnerships

Societal NeedsSocietal Needs Creative research (Idea Generation)

Creative research (Idea Generation)

Innovation(Idea Implementation)

Innovation(Idea Implementation)

• 27 JPND Members

• Member States

• Assoc. Countries

• Third Countries

• Eur. Commission

• Industry

• Public and Users

• 27 JPND Members

• Member States

• Assoc. Countries

• Third Countries

• Eur. Commission

• Industry

• Public and Users

• Common Strategy

• Transnational Calls

• Alignment Actions

• National Plans

• Communication +

Dissemination

• Common Strategy

• Transnational Calls

• Alignment Actions

• National Plans

• Communication +

Dissemination

• New treatments +preventive strategies

• Improved health + social care approaches

• De-stigmatize ND• Alleviate economic and

social burden

• New treatments +preventive strategies

• Improved health + social care approaches

• De-stigmatize ND• Alleviate economic and

social burden

PARTNERSHIP ACTIONS OUTCOMES

JPND ResearchJPND Research

Basic Clinical Healthcare/SocialBasic Clinical Healthcare/Social